Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.85 |
| ▸ | POLB | P06746 | 1/20 | 0.79 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.62 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.62 |
| ▸ | TNF | P01375 | 2/20 | 0.62 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.62 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | NOS2 | P35228 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196399 | 0.92 | CXCR4 (1.00) | CXCR4POLBTLR8HTTCYP1A2 | |
| SCHEMBL7164854 | 0.92 | CXCR4 (0.93) | CXCR4POLBTLR8HTTCYP1A2 | |
| SCHEMBL14447553 | 0.90 | CXCR4 (0.96) | CXCR4POLBTLR8HTTCYP1A2 | |
| SCHEMBL13801517 | 0.90 | CXCR4 (0.77) | CXCR4POLBTLR8HTTCYP1A2 | |
| SCHEMBL6197634 | 0.90 | CXCR4 (0.96) | CXCR4POLBTLR8HTTCYP1A2 | |
| SCHEMBL1520381 | 0.89 | POLB (1.00) | CXCR4POLBTLR8HTTCYP1A2 | |
| SCHEMBL11715808 | 0.87 | CXCR4 (0.72) | CXCR4POLBTLR8HTTCYP1A2 | |
| SCHEMBL22121330 | 0.87 | CXCR4 (0.72) | CXCR4POLBTLR8HTTCYP1A2 | |
| SCHEMBL17329351 | 0.87 | CXCR4 (0.72) | CXCR4POLBTLR8HTTCYP1A2 | |
| SCHEMBL3400537 | 0.87 | CXCR4 (0.66) | CXCR4POLBTLR8HTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1091942-B1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH AS (DK) | 2005-03-30 | — | — | EP | claimed |
| US-20020137784-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-09-26 | — | — | US | claimed |
| US-20020049246-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-04-25 | — | — | US | claimed |
| EP-1091942-B1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH AS (DK) | 2005-03-30 | — | — | EP | disclosed |
| US-6569880-B2 | Guanidine derivatives | NEUROSEARCH A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| US-20020137784-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-09-26 | — | — | US | disclosed |
| US-6380180-B1 | BENZIMIDAZOLE COMPOUNDS FOR TREATMENT OF ASTHMA, VASOSPASM, MEMORY LOSS, MIGRAINE AND OTHERS DISEASES ASSOCIATED WITH POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2002-04-30 | — | — | US | disclosed |
| US-20020049246-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-04-25 | — | — | US | disclosed |
| US-6194447-B1 | ASTHMA, ANTICONVULSANTS, COGNITION ACTIVATORS, BRAIN DISORDERS, PSYCHOLOGICAL DISORDERS, CARDIOVASCULAR DISORDERS,GASTROINTESTINAL DISORDERS | NEUROSEARCH A/S (DK) | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137784-A1 | Potassium channel blocking agents | KCNH2, KCNH3, KCND2 | CXCR4 1043/4885POLB 330/4885TLR8 3348/4885 |
| US-20020049246-A1 | Potassium channel blocking agents | KCNH2, KCNH3, KCND2 | CXCR4 1043/4885POLB 330/4885TLR8 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.